Precision Medicine for Heart Failure with Preserved Ejection Fraction: An Overview

Sanjiv J. Shah

doi:10.1007/s12265-017-9756-y

Precision Medicine for Heart Failure with Preserved Ejection Fraction: An Overview

Sanjiv J. Shah^*

^*Corresponding author for this work

Medicine, Cardiology Division

Research output: Contribution to journal › Article › peer-review

75 Scopus citations

Abstract

There are few proven therapies for heart failure with preserved ejection fraction (HFpEF). The lack of therapies, along with increased recognition of the disorder and its underlying pathophysiology, has led to the acknowledgement that HFpEF is heterogeneous and is not likely to respond to a one-size-fits-all approach. Thus, HFpEF is a prime candidate to benefit from a precision medicine approach. For this reason, we have assembled a compendium of papers on the topic of precision medicine in HFpEF in the Journal of Cardiovascular Translational Research. These papers cover a variety of topics relevant to precision medicine in HFpEF, including automated identification of HFpEF patients; machine learning, novel molecular approaches, genomics, and deep phenotyping of HFpEF; and clinical trial designs that can be used to advance precision medicine in HFpEF. In this introductory article, we provide an overview of precision medicine in HFpEF with the hope that the work described here and in the other papers in this special theme issue will stimulate investigators and clinicians to advance a more targeted approach to HFpEF classification and treatment.

Original language	English (US)
Pages (from-to)	233-244
Number of pages	12
Journal	Journal of Cardiovascular Translational Research
Volume	10
Issue number	3
DOIs	https://doi.org/10.1007/s12265-017-9756-y
State	Published - Jun 1 2017

Funding

Dr. Shah is supported by National Institutes of Health R01 HL107577 and R01 HL127028 and American Heart Association #16SFRN28780016 and #15CVGPSD27260148. Dr. Shah has received research grants from Actelion, AstraZeneca, Corvia, and Novartis and consulting fees from Actelion, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Cardiora, Eisai, Ironwood, Merck, MyoKardia, Novartis, Pfizer, Sanofi, and United Therapeutics.

Keywords

Cluster analysis
Heart failure with preserved ejection fraction
Machine learning
Precision medicine
Treatment

ASJC Scopus subject areas

Molecular Medicine
Genetics
Pharmaceutical Science
Cardiology and Cardiovascular Medicine
Genetics(clinical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s12265-017-9756-y

Cite this

@article{d8638eba292644d0b3ebcf3865c4d1f7,

title = "Precision Medicine for Heart Failure with Preserved Ejection Fraction: An Overview",

abstract = "There are few proven therapies for heart failure with preserved ejection fraction (HFpEF). The lack of therapies, along with increased recognition of the disorder and its underlying pathophysiology, has led to the acknowledgement that HFpEF is heterogeneous and is not likely to respond to a one-size-fits-all approach. Thus, HFpEF is a prime candidate to benefit from a precision medicine approach. For this reason, we have assembled a compendium of papers on the topic of precision medicine in HFpEF in the Journal of Cardiovascular Translational Research. These papers cover a variety of topics relevant to precision medicine in HFpEF, including automated identification of HFpEF patients; machine learning, novel molecular approaches, genomics, and deep phenotyping of HFpEF; and clinical trial designs that can be used to advance precision medicine in HFpEF. In this introductory article, we provide an overview of precision medicine in HFpEF with the hope that the work described here and in the other papers in this special theme issue will stimulate investigators and clinicians to advance a more targeted approach to HFpEF classification and treatment.",

keywords = "Cluster analysis, Heart failure with preserved ejection fraction, Machine learning, Precision medicine, Treatment",

author = "Shah, {Sanjiv J.}",

note = "Funding Information: Dr. Shah is supported by National Institutes of Health R01 HL107577 and R01 HL127028 and American Heart Association #16SFRN28780016 and #15CVGPSD27260148. Funding Information: Dr. Shah has received research grants from Actelion, AstraZeneca, Corvia, and Novartis and consulting fees from Actelion, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Cardiora, Eisai, Ironwood, Merck, MyoKardia, Novartis, Pfizer, Sanofi, and United Therapeutics. Publisher Copyright: {\textcopyright} 2017, Springer Science+Business Media New York.",

year = "2017",

month = jun,

day = "1",

doi = "10.1007/s12265-017-9756-y",

language = "English (US)",

volume = "10",

pages = "233--244",

journal = "Journal of Cardiovascular Translational Research",

issn = "1937-5387",

publisher = "Springer",

number = "3",

}

TY - JOUR

T1 - Precision Medicine for Heart Failure with Preserved Ejection Fraction

T2 - An Overview

AU - Shah, Sanjiv J.

N1 - Funding Information: Dr. Shah is supported by National Institutes of Health R01 HL107577 and R01 HL127028 and American Heart Association #16SFRN28780016 and #15CVGPSD27260148. Funding Information: Dr. Shah has received research grants from Actelion, AstraZeneca, Corvia, and Novartis and consulting fees from Actelion, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Cardiora, Eisai, Ironwood, Merck, MyoKardia, Novartis, Pfizer, Sanofi, and United Therapeutics. Publisher Copyright: © 2017, Springer Science+Business Media New York.

PY - 2017/6/1

Y1 - 2017/6/1

N2 - There are few proven therapies for heart failure with preserved ejection fraction (HFpEF). The lack of therapies, along with increased recognition of the disorder and its underlying pathophysiology, has led to the acknowledgement that HFpEF is heterogeneous and is not likely to respond to a one-size-fits-all approach. Thus, HFpEF is a prime candidate to benefit from a precision medicine approach. For this reason, we have assembled a compendium of papers on the topic of precision medicine in HFpEF in the Journal of Cardiovascular Translational Research. These papers cover a variety of topics relevant to precision medicine in HFpEF, including automated identification of HFpEF patients; machine learning, novel molecular approaches, genomics, and deep phenotyping of HFpEF; and clinical trial designs that can be used to advance precision medicine in HFpEF. In this introductory article, we provide an overview of precision medicine in HFpEF with the hope that the work described here and in the other papers in this special theme issue will stimulate investigators and clinicians to advance a more targeted approach to HFpEF classification and treatment.

AB - There are few proven therapies for heart failure with preserved ejection fraction (HFpEF). The lack of therapies, along with increased recognition of the disorder and its underlying pathophysiology, has led to the acknowledgement that HFpEF is heterogeneous and is not likely to respond to a one-size-fits-all approach. Thus, HFpEF is a prime candidate to benefit from a precision medicine approach. For this reason, we have assembled a compendium of papers on the topic of precision medicine in HFpEF in the Journal of Cardiovascular Translational Research. These papers cover a variety of topics relevant to precision medicine in HFpEF, including automated identification of HFpEF patients; machine learning, novel molecular approaches, genomics, and deep phenotyping of HFpEF; and clinical trial designs that can be used to advance precision medicine in HFpEF. In this introductory article, we provide an overview of precision medicine in HFpEF with the hope that the work described here and in the other papers in this special theme issue will stimulate investigators and clinicians to advance a more targeted approach to HFpEF classification and treatment.

KW - Cluster analysis

KW - Heart failure with preserved ejection fraction

KW - Machine learning

KW - Precision medicine

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=85020182387&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020182387&partnerID=8YFLogxK

U2 - 10.1007/s12265-017-9756-y

DO - 10.1007/s12265-017-9756-y

M3 - Article

C2 - 28585183

AN - SCOPUS:85020182387

SN - 1937-5387

VL - 10

SP - 233

EP - 244

JO - Journal of Cardiovascular Translational Research

JF - Journal of Cardiovascular Translational Research

IS - 3

ER -

Precision Medicine for Heart Failure with Preserved Ejection Fraction: An Overview

Abstract

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this